Ischemia-Modified Albumin in Diabetic Foot Ulcers: Promising Marker or Incomplete Picture?
Summary: A letter by **Seshadri Reddy Varikasuvu, PhD** (AIIMS, Deoghar) published in *International Journal of Lower Extremity Wounds* (ahead of print, August 2025) critically examines a study by Juttada et al. that explored serial monitoring of ischemia-modified albumin (IMA) as a biomarker for healing in diabetic foot ulcers (DFUs).
Key Reflections:
- Varikasuvu acknowledges the novelty of using serial IMA measurements to reflect wound healing dynamics.
- However, he raises concerns about the study’s predictive validity, noting limitations such as inadequate adjustment for baseline albumin levels and neglect of oxidative therapies like hyperbaric oxygen therapy.
- The letter recommends that future biomarker research in DFUs should adopt a multi-marker strategy and account for oxidative stress variability to strengthen clinical utility.
Read the full letter in *International Journal of Lower Extremity Wounds*
Keywords:
ischemia-modified albumin (IMA),
diabetic foot ulcer,
biomarkers,
oxidative stress,
hyperbaric oxygen therapy,
wound healing monitoring